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Abstract
HIV is a devastating human pathogen that causes serious immunological diseases in humans around
the world. The virus is able to remain latent in an infected host for many years, allowing for the
long-term survival of the virus and inevitably prolonging the infection process. The location and
mechanisms of HIV latency are under investigation and remain important topics in the study of viral
pathogenesis. Given that HIV is a blood-borne pathogen, a number of cell types have been
proposed to be the sites of latency, including resting memory CD4+ T cells, peripheral blood
monocytes, dendritic cells and macrophages in the lymph nodes, and haematopoietic stem cells in
the bone marrow. This review updates the latest advances in the study of HIV interactions with
monocytes and dendritic cells, and highlights the potential role of these cells as viral reservoirs and
the effects of the HIV-host-cell interactions on viral pathogenesis.
Background
Human immunodeficiency virus (HIV) remains a devas-
tating human pathogen responsible for a world-wide pan-
demic of acquired immunodeficiency syndrome (AIDS).
Despite extensive research of HIV since the virus was iden-
tified over 25 years ago, eradication of HIV-1 infection
and treatment of AIDS remain a long-term challenge
[1,2]. The AIDS pandemic has stabilised on a global scale.
In 2007, it was estimated that 30 to 36 million people
world-wide were living with HIV, and 2.7 million people
were newly infected with HIV. Moreover, AIDS-related
deaths were increased from an estimated 1.7 million peo-
ple in 2001 to 2.0 million in 2007. Africa continues to be
over-represented in the statistics, with 68% of all HIV-pos-
itive people living in sub-Saharan countries. The young
generation represents a large proportion of newly infected
population who may contribute to the overall spread of
HIV in the future [3].
There are two types of HIV, HIV-1 and HIV-2; both are
capable of causing AIDS, but HIV-2 is slightly attenuated
with regards to disease progression [4]. Given the relative
severity of HIV-1 infection, the majority of studies have
been done using HIV-1. The infection dynamics of HIV-1
are very interesting. Upon initial HIV-1 infection, there is
a period of continuous viral replication and strong
immune pressure against the virus, resulting in a relatively
low steady state of viral load. The virus then enters a
chronic stage, wherein there is limited virus replication
and no outward signs of disease. This clinical phase can
last many years, ultimately leading to destruction of the
host immune system due to chronic activation or viral
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replication. This results in the onset of the AIDS stage with
opportunistic infections and inevitable death in the vast
majority of untreated patients [4].
Unfortunately, there is no effective AIDS vaccine currently
available, and antiretroviral therapy is limited in its ability
to fully control viral replication in infected individuals.
Recent progress suggests that understanding how HIV
interacts with the host immune cells is vitally important
for the development of new treatments and effective vac-
cination regimens [1,2]. Monocytes, monocyte-differenti-
ated dendritic cells (DCs) and macrophages are critical
immune cells responsible for a wide range of both innate
and adaptive immune functions [5]. These cell types also
play multifaceted roles in HIV pathogenesis (Table 1). In
this review, the potential roles of monocytes and DCs as
HIV reservoirs and in latency will be discussed in detail.
Monocytes interact with HIV-1
Monocyte distribution and function
Monocytes are vitally important cells in the immune sys-
tem, as they are the precursor cells to professional antigen-
presenting cells (APCs), such as macrophages and DCs.
These types of immune cells patrol the bloodstream and
tissues, replenishing dying APCs or, in an infection, pro-
viding enough of these cells for the body to effectively
combat an invading pathogen [5]. Undifferentiated
monocytes live for only a few days in the bloodstream.
Upon differentiation or activation, the life-span of mono-
cytes is significantly prolonged for up to several months
[6].
There are two major subtypes of monocytes, those that are
highly CD14-positive (CD14++CD16-) and those that are
CD16-positive (CD14+CD16+). CD16+ cells make up only
a small percentage (around 5%) of the total monocyte
population, but they are characterised as more pro-
inflammatory and having a greater role in infections than
the CD14++CD16- cells [7].
HIV infection of monocyte
Although monocytes express the required HIV-1 receptors
and co-receptors for productive infection [8,9], they are
not productively infected by HIV-1 in vitro. This is possibly
due to an overall inefficiency in each of the steps required
for virus infection, ranging from viral entry to proviral
DNA integration [10-12], but not due to a viral nucleocap-
sid uncoating defect [13]. Recent studies have suggested a
role for naturally occurring anti-HIV micro-RNA (miRNA)
in suppressing HIV-1 replication in peripheral blood
mononuclear cells or purified monocytes [14-17]. This
mechanism could allow for further studies utilising miR-
Table 1: Myeloid lineage cell types and their potential roles and proposed mechanisms in HIV-1 latency
Cell types Primary Locations Cellular markers Potential role in HIV latency and 
proposed mechanisms
References
Monocytes Peripheral blood CD14++
or CD16+CD14+
YES, but possibly mainly in CD16+ cells
• Restricted HIV-1 replication at different 
steps of viral life-cycle
￿ Low molecular weight APOBEC3G (CD16+ 
only)
￿ Low level or undetectable Cyclin T1
￿ Impaired phosphorylation of CDK9
[10-12,87-92,94]
Macrophages Mucosal surface/tissues CD14-
EMR1+
CD68+
NO
￿ High level Cyclin T1
￿ Phosphorylation of CDK9 and active P-TEFb
[14,18,94,97]
Myeloid DCs Peripheral blood (immature)
Lymph node (mature)
CD11c+
CD123-
BDCA1+
YES
￿ Low level virus replication
￿ Lymph node biopsies reveal presence
￿ Unknown mechanism
[101,107,112]
Plasmacytoid DCs Peripheral blood (immature)
Lymph node (mature)
CD11c-
CD123+
BDCA2+
BDCA4+
Unlikely
￿ Inhibiting HIV-1 replication through the 
secretion of IFNα and an unidentified small 
molecule
￿ Unknown mechanism
[49,50,101]
Langerhans cells Mucosal surface and epidermal tissue CD1a+
Langerin+
Unlikely
￿ Langerin inhibits virus transmission and 
enhances virus take-up and degradation
￿ May act differently in co-infections
[40,41,113]
EMR1, epidermal growth factor module-containing mucin-like receptor 1 (a G-protein coupled receptor); BDCA, blood DC antigen.Retrovirology 2009, 6:51 http://www.retrovirology.com/content/6/1/51
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NAs as inhibitors of HIV-1 [15]. However, it has also been
shown that HIV-1 is capable of suppressing some inhibi-
tory miRNAs [16], which may reflect an evolutional inter-
action between HIV-1 and host factors. Further studies are
required to understand this interaction and develop a
therapeutic approach against HIV-1 infection using miR-
NAs.
Differentiation of monocytes into macrophages or DCs in
vitro enables productive HIV-1 replication in the differen-
tiated cells [14,18,19]. Based on current understanding,
vaginal macrophages are more monocyte-like than intes-
tinal macrophages and show increased HIV-1 susceptibil-
ity [20]. Hence, some monocyte characteristics might be
required for efficient infection, and these traits may be lost
in fully differentiated tissue macrophages.
Monocyte-HIV interactions that impact immune function
Given the role of monocytes in the immune system and in
HIV-1 replication, a number of HIV-1 proteins have been
shown to affect the biology of monocytes.
HIV-1 Tat-mediated transactivation of the viral promoter
is essential for HIV-1 transcription [21]. Exogenous
recombinant HIV-1 Tat protein has been shown to
increase monocyte survival through increased expression
of the anti-apoptotic protein Bcl-2 [22]. Using an in vitro
model of monocyte death mediated by TRAIL (tumour
necrosis factor-alpha-related apoptosis inducing ligand),
it has been shown that HIV-1 Tat encourages the survival
of monocytes in situations where they would normally be
cleared [22]. Exogenous HIV-1 Tat has been shown to
cause production of the cytokine interleukin (IL)-10 from
monocytes in vitro [23,24]. Significantly increased IL-10
levels were also observed in HIV/AIDS patients compared
with healthy controls [25]. Furthermore, up-regulation of
IL-10 production in HIV/AIDS patients has been corre-
lated with increased levels of monocyte-secreted myeloid
differentiation-2 and soluble CD14 [25]; both proteins
are key molecules in the immune recognition of gram-
negative bacterial lipopolysaccharide (LPS). Given that
high levels of secreted CD14 have been associated with
impaired responses to LPS [26], it has been proposed that
the release of general immunosuppressant IL-10 by
monocytes [27] facilitates the progression to AIDS [25].
HIV-1 Nef is a multifunctional accessory protein that
plays an important role in viral pathogenesis [28]. Retro-
viral-mediated HIV-1 Nef expression in primary mono-
cytes and a promonocytic cell line inhibits LPS-induced
IL-12p40 transcription by inhibiting the JNK mitogen-
activated protein kinases [29]. As an inducible subunit of
biologically active IL-12, IL-12p40 plays a critical role in
the development of cellular immunity, and its production
is significantly decreased during HIV-1 infection [29]. This
study implicates the importance of HIV-1 Nef in the loss
of immune function and progression to AIDS.
HIV-1 matrix protein (p17) regulates a number of cellular
responses and interacts with the p17 receptor (p17R)
expressed on the surface of target cells [30]. Upon binding
to the cell surface receptor p17R, exogenous HIV-1 matrix
protein causes secretion of the chemokine monocyte
chemotactic protein-1 (MCP-1, also known as CCL2)
from monocytes [30]. MCP-1 potentially increases mono-
cyte recruitment to the sites of HIV-1 infection, increasing
the available monocyte pool for infection by HIV-1; this
recruitment may be of critical importance given the rela-
tively low rate of infection of this cell type [10-12].
HIV-1 and HIV-1-derived factors have been shown also to
induce up-regulation of programmed death ligand-1 on
monocytes in vitro [31,32]. This ligand, in complex with
its receptor, programmed death-1, causes apoptosis of all
T cell types [33] and a loss of anti-viral function in a man-
ner similar to known immunosuppressive cytokines [34].
Together, these studies suggest that HIV-1 can impair
virus-specific immunity by modulating immuno-regula-
tory molecules of monocytes and T cells.
Of the studies discussed above, those involving Tat,
matrix protein and HIV-1-derived factors, were performed
using recombinant or purified proteins, whereas the Nef
study and the reports on the programmed death ligand-1
were performed using infectious viruses and nef-deleted
HIV-1 mutants. Although these results shed light on the
influence of individual viral proteins on monocytes in
vitro, synergistic or antagonistic effects of HIV-1 proteins
on cellular responses cannot be ruled out, nor can the
roles played by other host factors in vivo be excluded.
Overall, HIV-1 appears to promote the survival of mono-
cytes as a key step for viral persistence. The interactions
between the virus and monocytes may contribute key
functions in establishing chronic HIV-1 infection and
facilitating the progression to AIDS. These outcomes are
likely influenced by the altered immunological function
of monocytes and their interactions with other types of
HIV-1 target cells (Figure 1).
DCs interact with HIV
Immune function of DCs
DCs are professional APCs that are differentiated from
monocytes in specific cytokine environments. DCs bridge
the innate and adaptive immune responses, as they endo-
cytose and break down invading pathogens in the
endolysosome or proteasome and present antigen frag-
ments to T cells, usually in the context of major histocom-
patability complexes [5]. There are three major DC
subtypes: myeloid DCs, plasmacytoid DCs (pDC), andRetrovirology 2009, 6:51 http://www.retrovirology.com/content/6/1/51
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Langerhans cells. These DC subtypes are characterised
based on their locations, surface markers and cytokine
secretion profiles [5].
DC life-span and survival are highly dependent on their
anatomical locations and the DC subtypes [35]. In gen-
eral, DC half-lives measure up to a few weeks, and they
can be replaced through proliferating hematopoietic pro-
genitors, monocytes, or tissue resident cells [35]. It has
been shown that productive HIV-1 replication occurs in
human monocyte-derived DCs for up to 45 days [36].
DCs may survive longer within the lymph nodes due to
cytokine stimulation in the microenvironment, which
may help spread HIV-1 infection and maintain viral reser-
voirs.
HIV infection of DCs
HIV-1 is capable of directly infecting different DC sub-
types (known as cis infection), but at a lower efficiency
than HIV-1's ability to infect activated CD4+ T cells; there-
fore, only a small percentage of circulating DCs are posi-
tive for HIV in infected individuals [19]. Productive HIV-
1 replication is dependent on fusion-mediated viral entry
in monocyte-derived DCs [37], and mature HIV-1 parti-
cles are localised to a specialised tetraspanin-enriched
sub-compartment within the DC cytoplasm [38].
Langerhans cells are present in the epidermis or mucosal
epithelia as immune sentinels [39]. It is interesting that
Langerhans cells have been shown to be resistant to HIV-
1 infection [40]. This resistance appears to be due to the
expression of Langerin, which causes internalisation and
break-down of HIV-1 particles and blocks viral transmis-
sion [40]. However, in the context of co-infection with
other sexually transmitted organisms, such as the bacte-
rium Neisseria gonorrhoeae and/or the fungus Candida alba-
cans  [41] or when stressed by skin abrasion [42],
Langerhans cells can become more susceptible to HIV-1
Locations of HIV-1 replication and latency and routes of transmission between haematopoietic cell populations Figure 1
Locations of HIV-1 replication and latency and routes of transmission between haematopoietic cell popula-
tions. All cell types shown are susceptible to HIV-1 entry and integration of the proviral DNA. Some anatomical locations are 
shown; those outside of marked areas are in the bloodstream, lymphatic system and/or tissues. Black arrows represent differ-
entiation and/or maturation and may represent more than one step and could involve multiple intermediate cell types. Purple 
arrows represent routes of trans infection, and relative rates are shown as high or low. "Rep" indicates productive HIV-1 repli-
cation with relative rates shown as high or low. HIV-1 cis infection routes are not shown, as any susceptible cell may be 
infected by productive replication from another cell. Those cells in which HIV-1 latency is thought to occur should be consid-
ered as putative viral reservoirs and therapeutic targets.Retrovirology 2009, 6:51 http://www.retrovirology.com/content/6/1/51
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infection and are able to transmit HIV-1 to CD4+ T cells
effectively [42].
Drug abuse can significantly facilitate HIV infection,
transmission and AIDS progression through drug-medi-
ated immunomodulation. Recent studies have suggested
that the recreational drug, methamphetamine, increases
susceptibility of monocyte-derived DCs to HIV-1 infec-
tion in vitro [43] and blocks the antigen presentation func-
tion of DCs [44]. Although its relevance to the in vivo
situation is unclear, this finding is potentially a further
risk factor (aside from the use of contaminated needles,
etc.) associated with drug use and may explain the high
levels of HIV-prevalence among drug abusers.
HIV-1 infection of DCs likely contributes to viral patho-
genesis. Notably, HIV-2 is much less efficient than HIV-1
at infecting both myeloid DCs and pDCs, whilst retaining
its infectivity of CD4+ T cells [45]. This observation offers
an explanation for the decreased pathogenicity of HIV-2,
since HIV-2 will need to infect CD4+ T cells directly and,
perhaps more importantly, resting or memory CD4+ T
cells to ensure long-term survival of the virus.
DC-HIV interactions that impact the immune function
Given the important roles DCs play in the immune
response, it is reasonable that HIV-1 proteins or the virus
itself have been shown to affect the function of DCs in
vitro. Both HIV-1 matrix and Nef proteins have been
shown to cause only partial maturation of pDCs in vitro
[46,47]. In the presence of these viral proteins, DCs
acquire a migratory phenotype, facilitating travel to the
lymph nodes. However, these DCs do not express
increased levels of activation markers, such as the T cell
co-stimulatory molecules CD80 and CD86, or MHC class
II, that would lead to a protective immune response
[46,47]. It is possible, therefore, that the DCs are trapped
in the lymph nodes and unable to initiate a protective
immune response against the virus. The study of Nef pro-
tein's effects on DCs [47] was performed using a mouse
DC model in vitro and an immortalised cell line; hence the
full relevance of this finding to the in vivo situation is
unclear.
Conversely, recombinant Nef protein appears to cause DC
activation and differentiation by up-regulating the expres-
sion of CD80, CD86, MHC class II and other markers, as
well as various cytokines and chemokines associated with
T cell activation [48]. These effects have led to the propo-
sition that Nef protein is capable of causing bystander
activation of T cells via DCs [48], although this activity has
not been demonstrated experimentally. Of note, the
above study was performed using recombinant Nef alone.
DCs could contribute largely to an anti-HIV innate immu-
nity. It has been demonstrated that pDCs are capable of
inhibiting HIV-1 replication in T cells when cultured
together in vitro [49,50], implicating the importance of
pDCs for viral clearance. HIV-1 infected individuals are
known to have lower levels of circulating pDCs compared
with those of uninfected individuals [51]. It has been con-
firmed that HIV-1 is capable of directly killing pDCs [49],
illustrating that the virus can remove a potential block to
its replication and dissemination in pDCs.
HIV-1 can block CD4+ T cell proliferation or induce the
differentiation of naive CD4+ T cells into T regulatory cells
through pDCs [52,53]. These mechanisms involve HIV-1-
induced expression of indoleamine 2,3-deoxygenase in
pDCs. Indoleamine 2,3-deoxygenase is a CD4+ T cell sup-
pressor and regulatory T cell activator [52,53]. HIV-1
envelope protein gp120 has also been shown to inhibit
activation of T cells by monocyte-derived DCs [54], sug-
gesting that gp120 may also have a role in the suppression
of T cell function and progression to AIDS.
In addition, HIV-1 has been shown to suppress the
immune function of pDCs in general by suppressing acti-
vation of the anti-viral toll-like receptor 7 (TLR7) and
TLR8 [55], and by blocking the release of the anti-viral
interferon alpha [56]. A recent study indicated that diver-
gent TLR7 and TLR9 signalling and type I interferon pro-
duction in pDCs contribute to the pathogenicity of simian
immunodeficiency virus (SIV) infection in different spe-
cies of macaques [57]. These results suggest that chronic
stimulation of pDCs by SIV or HIV in non-natural hosts
may induce immune activation and dysfunction in AIDS
progression [57]. Overall, HIV-1 inhibits the function of
pDCs to allow maintenance of the virus within the host.
DC-mediated HIV-1 trans infection
The most interesting aspect of HIV-1 infection in DCs is
the ability of the cells to act as mediators of trans infection
of activated CD4+ T cells, which is the most productive cell
type for viral replication. DC-mediated HIV-1trans infec-
tion of CD4+ T cells is functionally distinct from cis infec-
tion [58,59] and involves the trafficking of whole virus
particles from the DCs to the T cells via a 'virological syn-
apse' [59,60]. Previous reviews have summarised the
understanding of HIV-DC interactions [19,61]; so here we
focus on discussing the latest progress in this field.
DC-mediated HIV-1 trans  infection of CD4+ T cells is
dependent on, or enhanced by, a number of other cellular
and viral factors. CD4 co-expression with DC-SIGN (DC-
specific intercellular adhesion molecule 3-grabbing non-
integrin), a C-type lectin expressed on DCs, inhibits DC-
mediated trans infection by causing retention of viral par-
ticles within the cytoplasm [62]. HIV-1 Nef appears to
enhance DC-mediated HIV-1 trans-infection. Nef-
enhanced HIV-1 transmission efficiency correlates with
significant CD4 down-regulation in HIV-1-infected DCsRetrovirology 2009, 6:51 http://www.retrovirology.com/content/6/1/51
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[62]. Furthermore, the maturation state of the DCs
appears to be important for trans infection, with mature
DCs showing greater HIV trafficking ability than imma-
ture DCs [59,63-65]. These results have highlighted the
proposed model that immature DCs might endocytose
the virus in the periphery and then transfer it to CD4+ T
cells upon DC maturation in the lymph node [19].
Recent studies have revealed that the precise trafficking of
the endocytosed HIV virion, with regard to the sub-cellu-
lar vesicle trafficking networks [64] and cytoskeletal rear-
rangements associated with synapse formation [63], is
critical for trans infection in mature DCs. The host cell-
derived glycosphingolipid composition of the viral parti-
cle also appears to be important for both the capture of
virus in mature and immature DCs and the trans infection
process [66]. Our recent results suggest that intracellular
adhesion molecule-1 (ICAM-1), but not ICAM-2 or
ICAM-3, is important for DC-mediated HIV-1 transmis-
sion to CD4+ T cells [67]. The interaction between ICAM-
1 on DCs and leukocyte function-associated molecule 1
(LFA-1) on T cells plays an important role in DC-mediated
HIV-1 transmission [68]. This mechanism might be spe-
cific for DC-mediated transmission of HIV-1 to CD4+ T
cell, as in vitro experiments blocking LFA-1 on HIV-
infected CD4+ T cells have shown no effect on virus trans-
mission to non-infected T cells [69]. In addition, purified
host surfactant protein A in the mucosa has been shown
to enhance DC-mediated HIV-1 transfer by binding to the
viral envelope glycoprotein, gp120 [70]. This study also
showed that surfactant protein A inhibited the direct
infection of CD4+ T cells [70], suggesting a selection pres-
sure for DC-mediated trans infection at mucosal surfaces.
The precise mechanism of virus transfer from DCs to
CD4+ T cells has yet to be determined [19]. Recent studies
have demonstrated a role for small lipid vesicles known as
exosomes in immature and mature DC-mediated HIV-1
transmission to CD4+ T cells [66,71,72]. Immature DCs
are capable of constitutively releasing infectious virus in
association with exosomes in the absence of CD4+ T cells
[71]. HIV-1 and purified exosomes can be endocytosed by
mature DCs into the same intracellular compartment and
transferred to co-cultured CD4+ T cells [72], suggesting
that HIV-1 may exploit an intrinsic exosome trafficking
pathway in mature DCs to facilitate viral dissemination.
Although interesting for infectious dynamics, these obser-
vations on exosome-mediated viral transmission do not
sufficiently explain the mechanisms of HIV-1 trans infec-
tion. How these models relate to the in vivo situation of
DC-mediated HIV-1 transmission is unclear, given that
DCs can traffic to the lymph node and effectively transfer
virus to CD4+ T cells [19]. If DCs release HIV-1 in associa-
tion with exosomes in the tissue as DCs migrate to lymph
nodes [71], or if DCs require T cell activation for the
release of exosome-associated HIV-1 [72], the viral trans-
mission process might be very inefficient in vivo.
Recent studies have also offered the intriguing possibility
that HIV-1 can be transferred from cell to cell via cell pro-
trusions, with the virus either transmitting via cellular
membrane nanotubes [73] or 'surfing' along the extracel-
lular surface of the cytoplasmic membrane [74]. HIV-1
intracellular trafficking is dependent on the viral envelope
protein on the membrane of an infected cell to form a sta-
ble complex with the protrusion from an uninfected cell
[73]. This mechanism of viral transmission may be an
adaptation of a normal cellular cross-talk process that is
used in normal cellular communication, for example, by
DCs and T cells during immunological synapse forma-
tion. Limitations to the above studies are that they were
performed in either CD4+ T cells alone [73], immortal
CD4+ T cells [74], or mainly using a mouse retroviral
model [74]. Indeed, the potential mechanisms of cell-cell-
mediated HIV transmission have yet to be investigated in
the DC-T cell trans infection model.
Inhibition of cell-cell mediated HIV-1 transmission can be
developed into future therapeutic approaches. Because of
the importance of DC-mediated trans infection of CD4+ T
cells, a number of recent studies have identified factors
that block this process, such as the C-type lectin, Mer-
maid, and natural anti-DC-SIGN antibodies in breast milk
[75-78]. However, the therapeutic efficacy of these factors
has yet to be established.
HIV-2 is incapable of being transferred from DCs [45];
and, coupled with its overall lack of cis infection of DCs,
these data may explain why HIV-2 is less pathogenic than
HIV-1.
Potential role of monocytes and DCs in HIV-1 
latency and reservoirs
In general, latency refers to the absence of gene expression
of a pathogen in the infected hosts or cells, serving to
ensure the long-term survival of the pathogen. Latency is
an important step for a number of viral pathogens includ-
ing HIV and other retroviruses [79-82]. Latency allows for
the release of new viruses over an extended period of time
and avoids short-term immune responses. The site of
latency can form a viral reservoir, from which a virus can
initiate new infections of naïve cells.
The critical aspect for supporting a viral reservoir is a cell
type that will stay alive for a long time in order to preserve
the virus. It has been shown that even with anti-retroviral
therapy, low levels of HIV-1 viremia are maintained
within the plasma of patients for at least 7 years [83].
Given that HIV-1 causes CD4+ T-cell depletion and com-
promised immunological functions associated with AIDSRetrovirology 2009, 6:51 http://www.retrovirology.com/content/6/1/51
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[84], most CD4+ T-cells are not sufficient for long-term
maintenance of the virus. However, long-lived memory
CD4+ T cells can play an important role in HIV-1 latency
[85,86]. This reservoir can persist for a long time during
antiretroviral treatment; indeed, one study has suggested
a viral half-life of 44 months [86], and another recent
study showed survival of virus in the reservoir for 8.3 years
without significant viral mutation [85]. These results sug-
gest that the viral reservoir is protected from antiretroviral
treatment and that it is capable of initiating new infec-
tions when the treatment is stopped.
Both monocytes and certain subsets of DCs have also
been proposed as sites of HIV-1 latency (Figure 1 and
Table 1).In vivo or ex vivo studies of HIV latency are gener-
ally performed using clinical samples from infected indi-
viduals undergoing antiretroviral therapy. The
antiretroviral therapy may clear any easily accessible rep-
licating virus and allow study of only the long-term HIV-l
reservoirs.
Role of monocytes
Monocytes are implicated as a viral reservoir based on the
detection of, or the recovery of, infectious virus from
monocytes isolated from HIV-positive individuals on
antiretroviral therapy [87-91]. It appears that CD16-posi-
tive monocytes (5% of monocyte population [7]) are both
more susceptible to infection and preferentially harbour
the virus long-term [92,93], perhaps explaining why only
small numbers of monocytes are infected by HIV-1 in
vitro. CD14++ monocytes express high levels of the low
molecular weight form of APOBEC3G (apolipoprotein B
mRNA-editing enzyme, catalytic polypeptide-like 3G),
which is associated with anti-HIV activity, whereas CD16+
monocytes express the high molecular weight form of
APOBEC3G that has no anti-HIV activity [92].
The mechanism of HIV-1 latency in monocytes is not fully
understood. Recent data suggest that the inhibition of
viral replication is host mediated, at least in part, through
a lack of the expression of key co-factors for the HIV-1 Tat
protein. It appears that the transcription of the integrated
viral genome, as transactivated by the viral Tat protein, is
inhibited [94]. Tat binds to the 5' long terminal repeat
sequence of the integrated genome in complex with two
host proteins, cyclin T1 (CycT1) and cyclin-dependent
kinase 9 (CDK9), collectively known as the positive tran-
scription elongation factor b (P-TEFb) [21,95,96]. Mono-
cytes, when compared with activated CD4+ T cells and
macrophages [96], are known to have much lower levels
of CycT1 expression [94,97], therefore, they lack func-
tional P-TEFb. However, this is not the only factor respon-
sible for the resistance of monocytes to HIV-1 replication,
as transient expression of CycT1 is not sufficient to restore
HIV-1 Tat-mediated transactivation in monocytes [94].
Cell-cell fusion of monocytes and a HIV-1-permissive cell
line restores Tat-mediated transactivation [94]. Phospho-
rylation of CDK9 is known to be vital for the formation of
a P-TEFb complex and for Tat-mediated transcription of
the HIV-1 promoter [98]. Despite having the same levels
of CDK9, monocytes have low levels of the active, phos-
phorylated CDK9 form as compared with macrophages,
and this phenotype has been directly correlated with the
poor ability of monocytes to support HIV-1 replication
[94]. In addition, the basal transcription from the HIV-1
LTR in undifferentiated primary monocytes was reported
to be undetectable using a transient transfection assay
[94].
Studying HIV-1 latency in monocytes is challenging due
to generally low viral integration and infection of mono-
cytes [94]. However, even when a HIV-1 proviral DNA
construct is transfected directly into monocytes, there is
no infectious virus production [94]. When monocytes dif-
ferentiate into macrophages, they become increasingly
susceptible to HIV-1 infection and permissive to viral gene
expression and production of infectious viruses [94]. Fur-
thermore, the differentiation of monocytes into macro-
phages stimulates HIV-1 production in the infected
monocytes [94], suggesting a role played by monocytes in
both viral latency and reactivation.
Contribution of DCs
Because of the ability of DCs to transfer virus to CD4+ T
cells, it is conceivable that DCs may act as reservoirs for
HIV-1 and 'dose' T cells with the virus over extended peri-
ods. DCs are capable of transmitting HIV-1 to T cells over
a period of several days, and the viral transmission is
dependent on viral replication [99-101]. It is possible,
therefore, that long-term transfer of HIV-1 to T cells is
actually through cis infection, while trans infection is only
present in the very early stages [58]. This HIV-1 transmis-
sion process may be 'trans-like', for example HIV-1 may
assemble in endosomes or other intracellular membrane
domains in a similar manner as described in macrophages
[102,103], then the virus may be transmitted across a viro-
logical synapse. However, the precise mechanism of virus
assembly within macrophages remains a source of debate
[104,105].
The ability of DCs to act as reservoirs of HIV-1 appears to
be highly dependent on the DC sub-type. Follicular DCs
(FDCs) have been shown to retain infectious viral parti-
cles on their surface, and the retained virus is capable of
being transferred to CD4+ T cells [106-110]. FDCs in HIV-
1 positive individuals harbour genetically diverse viral
strains that are not observed elsewhere in the body [111],
indicating that these cells may act as focal points for the
rapid emergence of mutations observed in HIV-1 infected
individuals.Retrovirology 2009, 6:51 http://www.retrovirology.com/content/6/1/51
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It also appears that peripheral blood myeloid DCs do not
harbour the virus in vivo during antiretroviral therapy
[112], suggesting that it is the DCs in the lymph nodes
that act as the long-term reservoir. This thinking is further
supported by other studies that found HIV-1 in associa-
tion with myeloid DCs that were isolated from lymph
node biopsies or necropsies of individuals on antiretrovi-
ral therapy [107]. Conversely, a recent study has suggested
that Langerhans cells isolated from the oral cavity of HIV-
1 positive individuals do not act as reservoirs for HIV-1,
despite HIV-1 detection within whole tissue samples from
the area [113]. This result is perhaps not surprising given
the effect of Langerin on inhibiting HIV-1 transmission
[40]. Moreover, pDCs have also not been implicated as
reservoirs of HIV-1, which may be due to inhibiting HIV-
1 replication through the secretion of IFNα and an uni-
dentified small molecule by pDCs [49,50].
Role of monocytic precursor cells
HIV-1 is capable of altering the biology of haematopoi-
etic stem cells in vivo, primarily affecting T cell develop-
ment [114-116]. Undifferentiated monocytic precursor
cells, such as CD34+ stem cells or partially differentiated
haematopoietic precursor cells, may act as reservoirs
[117,118]. These cells in the bone marrow will be rela-
tively shielded from antiviral treatments and may act as
the ultimate long-term reservoir of HIV-1 (Figure 1). This
mechanism allows for transmission of the virus because
the progenitor cells containing integrated HIV-1
genomes will proliferate, differentiate and pass on the
virus to progeny monocytes. Indeed, the ability to har-
bour genes and transfer them to progeny cells makes
stem cells attractive targets for gene therapy against HIV-
1 infection [119,120].
Other proposed mechanisms
There have been a number of studies that have proposed
other mechanisms for latency in CD4+ memory T cells. It
is possible that these mechanisms also have roles in
latency in monocytes and/or DCs, but this remains to be
investigated.
It has been proposed that the host cell itself can play a role
through inhibition of HIV-1 gene transcription. In a CD4+
T cell line and a yeast model of HIV-1 transcription, host
chromatin structures slowly accumulate (in one study
over 30 days [121]) on the long terminal repeat of the
integrated viral genome and inhibit viral gene transcrip-
tion [121,122]. Moreover, recent studies have suggested a
much broader role for host transcription factors in HIV-1
latency in CD4+ T cells [123-125].
In light of the evidence that suggests miRNAs play a role
in the resistance of monocytes to HIV-1 infection [14,15],
it is of interest that a number of host miRNAs have been
implicated in causing latency in resting primary CD4+ T
cells [126]. Inhibitors of these miRNAs are now being
touted as a new generation of treatment to be used in con-
cert with current antiretrovirals [reviewed in [127]].
In resting CD4+ T cells from HIV-1-infected individuals,
HIV-1 multiply spliced RNA transcripts are retained in the
nucleus and cannot be translated into functional proteins
[128]. The lack of a host transcription factor, polypyrimi-
dine tract binding protein, appears to account for the
underlying mechanism in resting CD4+ T cells. Transient
expression of this host protein induces productive HIV-1
replication in resting CD4+ T cells that are isolated from
HIV-1-positive individuals [128].
However, HIV-1 latency is not always restricted to resting
CD4+ T cells or explained by limiting cellular factors. In
some instances, HIV-1 latency is due to replicative selec-
tion for specific viral characteristics. It has been shown
that a doxycycline-dependent HIV-1 variant is capable of
establishing latency within a dividing CD4+ T cell type
(SupT1 cell line) normally permissive for viral replication
[129]. This study showed that only a small proportion
(0.1%–10%) of an inducible provirus was rescued from
the cells after addition of the inducing doxycycline drug,
indicating that HIV-1 is capable of establishing latency in
the majority of actively dividing cells. Thus, in some set-
tings, HIV-1 proviral latency is not limited to resting T
cells, but can be due to intrinsic viral traits [129].
Conclusion and future directions
Latency in HIV infection is a key area of study for under-
standing the pathogenesis and ultimate development of
therapies or vaccinations against HIV/AIDS. Figure 1
shows an overview of the known or proposed interactions
between HIV-1 and various cells of the haematopoietic
system. Moreover, myeloid lineage cell types and their
potential roles and proposed mechanisms in HIV-1
latency are summarized in Table 1.
Efforts to tackle HIV latency may ultimately fall into two
key areas, blocking the development of the latency and
reactivating viral reservoirs in chronically infected individ-
uals to clear the virus. Both aspects will require extensive
understanding of the mechanisms of HIV latency [1,2].
Given that monocytes and DCs have been implicated as
HIV-1 reservoirs using in vitro and ex vivo models of viral
infection (Table 1), further understanding of the mecha-
nisms of latency within these cells is an important area of
research. Although much is known about the ways in
which HIV-1 interacts with both monocytes and the vari-
ous types of DCs, some key questions remain to be
answered to fully understand the pathogenesis and
latency of HIV-1. For instance, the relative contributions
of the proposed cell types in the process of HIV latencyRetrovirology 2009, 6:51 http://www.retrovirology.com/content/6/1/51
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and molecular mechanisms in both viral and host aspects
remain to be elucidated.
The latent phase is of particular interest for the develop-
ment of novel anti-HIV interventions. The HIV and host-
factor interactions described here represent potential tar-
gets for both drug and vaccination efforts. Given that HIV-
1 has a very intimate relationship with host cells, blocking
known host factors responsible for certain viral effects
could have catastrophic consequences for the host. For
example, blocking DC factors responsible for virological
synapse formation may also switch off the formation of
the immunological synapses that arise in response to HIV
or other pathogen infections. The ultimate hope would be
to find either a viral factor or non-essential host factors
that can be removed without damage to the host. As a suc-
cessful example, the CCR5 co-receptor is now a target of
both HIV-1 gene therapy and antiretroviral therapy
[130,131]. Based on studies into the role of DCs in HIV-1
pathogenesis, there are also a number of post-exposure
vaccine clinical trials, wherein DCs are exposed ex vivo
with HIV-1 or HIV-1 antigens and then re-introduced into
the HIV-positive individual in an effort to elicit a protec-
tive immune response [reviewed in [132]].
Development of in vitro models of HIV-1 latency can be
extremely complex. While there are examples of complex
tissue culture models of in vivo systems for a range of
human pathogens, including HIV-1, these models involve
predominantly epithelial cells and various leukocytes
[133,134]. Cell culture-based models containing only
subsets of leukocytes have limitations, because it is
impossible to compartmentalise the cells in exactly the
same fashion as observed in vivo (as in lymph nodes, for
example). There are also many important technical issues
with isolation, maintenance and establishment of in vitro
studies of HIV-1 latency [reviewed in [135]].
In vivo or ex vivo model systems remain the best options
for studying long-term HIV-1 latency. SIV strains that are
closely related to HIV and display the same initial infec-
tion and latency characteristics can be used as attractive
models to study viral latency. Mice are generally not sus-
ceptible to HIV-1, or at least not in a physiologically rele-
vant manner. Recently, 'humanised' mice have become
available in HIV-1 research [reviewed in [136]]. The
humanised mouse model potentially offers a viable alter-
native to non-human primates for studying HIV-1 molec-
ular pathogenesis and for designing novel therapies that
block HIV-1 infection [137].
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